logo
Share SHARE
FONT-SIZE Plus   Neg

Par Pharmaceutical Closed Acquisition Of Privately Held Edict - Quick Facts

Generic drug maker Par Pharmaceutical Companies Inc. (PRX) said Friday it has completed the acquisition of privately-held Edict Pharmaceuticals Private Limited.

Par, based in New Jersey, said it paid $20.5 million at closing and $4.4 million repayment of certain pre-close indebtedness.

India-based Edict is a developer and manufacturer of solid oral dosage generic pharmaceuticals company, and currently has 11 ANDAs filed with the U.S. FDA.

In connection with the closing of the deal, a lawsuit by a former shareholder of Edict, Gavis Pharma LLC, was settled by the payment of a portion of the closing proceeds to Gavis by an Edict shareholder.

Par Pharmaceutical Companies Inc., is through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, develops high barrier-to-entry generic drugs and innovative proprietary pharmaceuticals.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Many apps are designed to enhance productivity, simplify social networking or provide other useful benefits. These apps are practical and functional. Others are shaping day-to-day lives. Thanks to these apps, the smartphones have already replaced the watch, calendar, calculator, address book, voice... The global app market would be worth $6.3 trillion by 2021, compared to $1.3 trillion in 2016, according to a new report from analyst firm App Annie. The expected growth in the global app market is said to reflect the significantly increasing number of smartphone owners and their use of mobile apps. Agricultural products giant Monsanto Co. on Wednesday reported a nearly 18 percent increase in profit for the third quarter from last year, reflecting strong sales growth in the agricultural productivity segment and a lower tax provision. Looking ahead, the company affirmed its outlook for fiscal 2017 ongoing earnings.
comments powered by Disqus
Follow RTT